The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Open accessAbstract
Neurofibromatosis type 1 (NF1) is a common genetic disorder that predisposes affected individuals to tumours. The NF1 gene encodes a RAS GTPase-activating protein called neurofibromin and is one of several genes that (when mutant) affect RAS–MAPK signalling, causing related diseases collectively known as RASopathies. Several RASopathies, beyond NF1, are cancer predisposition syndromes. Somatic NF1 mutations also occur in 5–10% of human sporadic cancers and may contribute to resistance to therapy. To highlight areas for investigation in RASopathies and sporadic tumours with NF1 mutations, we summarize current knowledge of NF1 disease, the NF1 gene and neurofibromin, neurofibromin signalling pathways and recent developments in NF1 therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Neurofibromatosis: Conference Statement
(1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520290115023 · Cited by 1,547
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,475
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
Von Recklinghausen Neurofibromatosis
Riccardi, V. M. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112313052704 · Cited by 1,344
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
The neurofibromatosis type 1 gene encodes a protein related to GAP
Xu, G., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90024-9 · Cited by 1,095
Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,094
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., Culver, M., Carey, J. C., Copeland, N. G., Jenkins, N. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90252-a · Cited by 1,082
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Evans, D. G., Howard, E., Giblin, C., Clancy, T., Spencer, H., Huson, S. M., & Lalloo, F. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33139 · Cited by 988
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
Martin, G. A., Viskoohil, D., Bollag, G., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R. M., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90150-d · Cited by 982
The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.
Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, M., & Collins, F. (1990) · Cell · doi:10.1016/0092-8674(90)90151-4 · Cited by 847
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
(1988) · PubMed · Cited by 817
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
VON RECKLINGHAUSEN NEUROFIBROMATOSIS: A CLINICAL AND POPULATION STUDY IN SOUTH-EAST WALES
HUSON, S. M., HARPER, P. S., & COMPSTON, D. A. S. (1988) · Brain · doi:10.1093/brain/111.6.1355 · Cited by 686
Brannan, C. I., Perkins, A. S., Vogel, K. S., Ratner, N., Nordlund, M. L., Reid, S. W., Buchberg, A. M., Jenkins, N. A., Parada, L. F., & Copeland, N. G. (1994) · Genes & Development · doi:10.1101/gad.8.9.1019 · Cited by 641
Self-citationLee, W., Teckie, S., Wiesner, T., Ran, L., Prieto Granada, C. N., Lin, M., Zhu, S., Cao, Z., Liang, Y., Sboner, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3095 · Cited by 619
Long-Term Follow-up of von Recklinghausen Neurofibromatosis
Sørensen, S. A., Mulvihill, J. J., & Nielsen, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604173141603 · Cited by 617
Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D., & Parada, L. F. (2001) · Genes & Development · doi:10.1101/gad.862101 · Cited by 604
Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
Use of the National Institutes of Health Criteria for Diagnosis of Neurofibromatosis 1 in Children
DeBella, K., Szudek, J., & Friedman, J. M. (2000) · Pediatrics · doi:10.1542/peds.105.3.608 · Cited by 581
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A., & Parada, L. F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.004 · Cited by 550
Listernick, R., Charrow, J., Greenwald, M., & Mets, M. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70122-9 · Cited by 548
Huson, S. M., Compston, D. A., Clark, P., & Harper, P. S. (1989) · Journal of Medical Genetics · doi:10.1136/jmg.26.11.704 · Cited by 540
A Clinical, Pathological, and Genetic Study of Multiple Neurofibromatosis
(1956) · Journal of the American Medical Association · doi:10.1001/jama.1956.02970230087029 · Cited by 522
Messiaen, L. M., Callens, T., Mortier, G., Beysen, D., Vandenbroucke, I., Van Roy, N., Speleman, F., & Paepe, A. D. (2000) · Human Mutation · doi:10.1002/1098-1004(200006)15:6<541::aid-humu6>3.0.co;2-n · Cited by 521
Miettinen, M., Fetsch, J. F., Sobin, L. H., & Lasota, J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176433.81079.bd · Cited by 507
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype
Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.-P., et al. (2007) · Nature Genetics · doi:10.1038/ng2113 · Cited by 472
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
CTCF Mediates Interchromosomal Colocalization Between Igf2/H19 and Wsb1/Nf1
Ling, J. Q., Li, T., Hu, J. F., Vu, T. H., Chen, H. L., Qiu, X. W., Cherry, A. M., & Hoffman, A. R. (2006) · Science · doi:10.1126/science.1123191 · Cited by 434
Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients
Friedman, J. M., & Birch, P. H. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970516)70:2<138::aid-ajmg7>3.0.co;2-u · Cited by 432
Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force
Friedman, J. M., Arbiser, J., Epstein, J. A., Gutmann, D. H., Huot, S. J., Lin, A. E., Mcmanus, B., & Korf, B. R. (2002) · Genetics in Medicine · doi:10.1097/00125817-200205000-00002 · Cited by 402
Menon, A. G., Anderson, K. M., Riccardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., & Li, F. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5435 · Cited by 395
Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen
Recklinghausen, F. V. (1882) · A. Hirschwald eBooks · Cited by 387
Easton, D. F., Ponder, M. A., Huson, S., & Ponder, B. A. J. (1993) · Europe PMC (PubMed Central) · Cited by 387
Molecular genetics of neurofibromatosis type 1 (NF1).
Shen, M. H., Harper, P. S., & Upadhyaya, M. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.1.2 · Cited by 377
Mouse Tumor Model for Neurofibromatosis Type 1
Vogel, K. S., Klesse, L. J., Velasco-Miguel, S., Meyers, K., Rushing, E. J., & Parada, L. F. (1999) · Science · doi:10.1126/science.286.5447.2176 · Cited by 372
Carli, M., Ferrari, A., Mattke, A., Zanetti, I., Casanova, M., Bisogno, G., Cecchetto, G., Alaggio, R., De Sio, L., Koscielniak, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4886 · Cited by 371
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow
Yang, F.-C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., et al. (2008) · Cell · doi:10.1016/j.cell.2008.08.041 · Cited by 364
Upadhyaya, M., Huson, S. M., Davies, M., Thomas, N., Chuzhanova, N., Giovannini, S., Evans, D. G., Howard, E., Kerr, B., Griffiths, S., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/510781 · Cited by 362
VON RECKLINGHAUSEN′S DISEASE AND PHEOCHROMOCYTOMAS
Walther, M. M., Herring, J., Enquist, E., Keiser, H. R., & Linehan, W. M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68171-2 · Cited by 361
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 359
Differential regulation of rasGAP and neurofibromatosis gene product activities
Bollag, G., & McCormick, F. (1991) · Nature · doi:10.1038/351576a0 · Cited by 341
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
Self-citationGain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome
Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., Ogata, T., Takada, F., Yano, M., Ando, T., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.05.021 · Cited by 330
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
Daston, M. M., Scrable, H., Nordlund, M., Sturbaum, A. K., Nissen, L. M., & Ratner, N. (1992) · Neuron · doi:10.1016/0896-6273(92)90270-n · Cited by 314
Self-citationFahsold, R., Hoffmeyer, S., Mischung, C., Gille, C., Ehlers, C., Kücükceylan, N., Abdel-Nour, M., Gewies, A., Peters, H., Kaufmann, D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302809 · Cited by 312
Association between benign and malignant peripheral nerve sheath tumors in NF1
Tucker, T., Wolkenstein, P., Revuz, J., Zeller, J., & Friedman, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000168830.79997.13 · Cited by 311
Elevated Risk for MPNST in NF1 Microdeletion Patients
De Raedt, T., Brems, H., Wolkenstein, P., Vidaud, D., Pilotti, S., Perrone, F., Mautner, V., Frahm, S., Sciot, R., & Legius, E. (2003) · The American Journal of Human Genetics · doi:10.1086/374821 · Cited by 310
Dasgupta, B., Yi, Y., Chen, D. Y., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4058 · Cited by 308
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors
Zhang, M., Wang, Y., Jones, S., Sausen, M., McMahon, K., Sharma, R., Wang, Q., Belzberg, A. J., Chaichana, K., Gallia, G. L., et al. (2014) · Nature Genetics · doi:10.1038/ng.3116 · Cited by 301
Tanaka, K., Nakafuku, M., Tamanoi, F., Kaziro, Y., Matsumoto, K., & Toh-e, A. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4303 · Cited by 292
Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study
Stiller, C., Chessells, J., & Fitchett, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.431 · Cited by 287
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Bajenaru, M. L., Hernandez, M. R., Perry, A., Zhu, Y., Parada, L. F., Garbow, J. R., & Gutmann, D. H. (2003) · PubMed · Cited by 275
Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos287 · Cited by 270
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Rescue of a Drosophila NF1 Mutant Phenotype by Protein Kinase A
The, I., Hannigan, G. E., Cowley, G. S., Reginald, S., Zhong, Y., Gusella, J. F., Hariharan, I. K., & Bernards, A. (1997) · Science · doi:10.1126/science.276.5313.791 · Cited by 255
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors
Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec‐Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20921 · Cited by 255
Serra, E. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.3055 · Cited by 254
Neurofibromin regulates G protein–stimulated adenylyl cyclase activity
Tong, J., Hannan, F., Zhu, Y., Bernards, A., & Zhong, Y. (2002) · Nature Neuroscience · doi:10.1038/nn792 · Cited by 248
IRA1, an inhibitory regulator of the RAS-cyclic AMP pathway in Saccharomyces cerevisiae.
Tanaka, K., Matsumoto, K., & Toh-E, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.2.757 · Cited by 245
Hyman, S. L., Arthur Shores, E., & North, K. N. (2006) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162206002131 · Cited by 244
Wu, J., Williams, J. P., Rizvi, T. A., Kordich, J. J., Witte, D., Meijer, D., Stemmer-Rachamimov, A. O., Cancelas, J. A., & Ratner, N. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.027 · Cited by 236
Self-citationRobertson, K. A., Nalepa, G., Yang, F.-C., Bowers, D. C., Ho, C. Y., Hutchins, G. D., Croop, J. M., Vik, T. A., Denne, S. C., Parada, L. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70414-x · Cited by 234
Hölzel, M., Huang, S., Koster, J., Øra, I., Lakeman, A., Caron, H., Nijkamp, W., Xie, J., Callens, T., Asgharzadeh, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.004 · Cited by 224
Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes
Kratz, C. P., Rapisuwon, S., Reed, H., Hasle, H., & Rosenberg, P. S. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30300 · Cited by 223
Seminog, O. O., & Goldacre, M. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.535 · Cited by 218
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients
Maertens, O., Prenen, H., Debiec-Rychter, M., Wozniak, A., Sciot, R., Pauwels, P., De Wever, I., Vermeesch, J. R., de Raedt, T., De Paepe, A., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl016 · Cited by 214
Hegedus, B., Dasgupta, B., Shin, J. E., Emnett, R. J., Hart-Mahon, E. K., Elghazi, L., Bernal-Mizrachi, E., & Gutmann, D. H. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.008 · Cited by 212
Miller, S. J., Rangwala, F., Williams, J., Ackerman, P., Kong, S., Jegga, A. G., Kaiser, S., Aronow, B. J., Frahm, S., Kluwe, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3330 · Cited by 211
Self-citationRequirement of Drosophila NF1 for Activation of Adenylyl Cyclase by PACAP38-Like Neuropeptides
Guo, H.-F., The, I., Hannan, F., Bernards, A., & Zhong, Y. (1997) · Science · doi:10.1126/science.276.5313.795 · Cited by 208
TORC1 Is Essential for NF1-Associated Malignancies
Johannessen, C. M., Johnson, B. W., Williams, S. M. G., Chan, A. W., Reczek, E. E., Lynch, R. C., Rioth, M. J., McClatchey, A., Ryeom, S., & Cichowski, K. (2008) · Current Biology · doi:10.1016/j.cub.2007.11.066 · Cited by 203
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 203
Evans, D. G. R., O'Hara, C., Wilding, A., Ingham, S. L., Howard, E., Dawson, J., Moran, A., Scott-Kitching, V., Holt, F., & Huson, S. M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.113 · Cited by 197
Buchberg, A. M., Cleveland, L. S., Jenkins, N. A., & Copeland, N. G. (1990) · Nature · doi:10.1038/347291a0 · Cited by 195
TP53 mutations are frequent in malignant NFI tumors
Legius, E., Dierick, H., Wu, R., Hall, B. K., Marynen, P., Cassiman, J., & Glover, T. W. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870100405 · Cited by 195
Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients
Rodriguez, F. J., Perry, A., Gutmann, D. H., O'Neill, B. P., Leonard, J., Bryant, S., & Giannini, C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318165eb75 · Cited by 190
Zhu, Y., Harada, T., Liu, L., Lush, M. E., Guignard, F., Harada, C., Burns, D. K., Bajenaru, M. L., Gutmann, D. H., & Parada, L. F. (2005) · Development · doi:10.1242/dev.02162 · Cited by 189
Next-generation sequencing identifies rare variants associated with Noonan syndrome
Chen, P.-C., Yin, J., Yu, H.-W., Yuan, T., Fernandez, M., Yung, C. K., Trinh, Q. M., Peltekova, V. D., Reid, J. G., Tworog-Dube, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324128111 · Cited by 186
Cell of Origin and Microenvironment Contribution for NF1-Associated Dermal Neurofibromas
Le, L. Q., Shipman, T., Burns, D. K., & Parada, L. F. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.017 · Cited by 185
GARG, S., LEHTONEN, A., HUSON, S. M., EMSLEY, R., TRUMP, D., EVANS, D. G., & GREEN, J. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12043 · Cited by 182
Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1
Prada, C. E., Rangwala, F. A., Martin, L. J., Lovell, A. M., Saal, H. M., Schorry, E. K., & Hopkin, R. J. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.08.051 · Cited by 182
Ingram, D. A., Yang, F.-C., Travers, J. B., Wenning, M. J., Hiatt, K., New, S., Hood, A., Shannon, K., Williams, D. A., & Clapp, D. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.181 · Cited by 181
Induction of Abnormal Proliferation by Nonmyelinating Schwann Cells Triggers Neurofibroma Formation
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D. K., & Zhu, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.002 · Cited by 170
Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis
McGillicuddy, L. T., Longo, J. F., Hollstein, P. E., Kubek, S., Beroukhim, R., Raedt, T. D., Johnson, B. W., Williams, S. M. G., Nghiemphu, P. L., Liau, L. M., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.009 · Cited by 170
Rahrmann, E. P., Watson, A. L., Keng, V. W., Choi, K., Moriarity, B. S., Beckmann, D. A., Wolf, N. K., Sarver, A. L., Collins, M. H., Moertel, C. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2641 · Cited by 169
Self-citationNeurofibromatosis type 1 and pregnancy
Dugoff, L., & Sujansky, E. (1996) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19961202)66:1<7::aid-ajmg2>3.0.co;2-r · Cited by 168
Regulatory Proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3
Ohba, Y., Mochizuki, N., Yamashita, S., Chan, A. M., Schrader, J. W., Hattori, S., Nagashima, K., & Matsuda, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000981200 · Cited by 168
The Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem Cells
Joseph, N. M., Mosher, J. T., Buchstaller, J., Snider, P., McKeever, P. E., Lim, M., Conway, S. J., Parada, L. F., Zhu, Y., & Morrison, S. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.003 · Cited by 167
Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., Caye‐Eude, A., Luca, A. D., Lepri, F. R., Dvorský, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu148 · Cited by 166
Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males
Sun, T., Warrington, N. M., Luo, J., Brooks, M. D., Dahiya, S., Snyder, S. C., Sengupta, R., & Rubin, J. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71048 · Cited by 161
Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1
Klose, A. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.8.1261 · Cited by 160
Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V.-F. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.04.008 · Cited by 159
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1
Stowe, I. B., Mercado, E. L., Stowe, T. R., Bell, E. L., Oses-Prieto, J. A., Hernández, H., Burlingame, A. L., & McCormick, F. (2012) · Genes & Development · doi:10.1101/gad.190876.112 · Cited by 159
Mo, W., Chen, J., Patel, A. J., Zhang, L., Chau, V., Li, Y., Cho, W., Lim, K., Xu, J., Lazar, A. J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.053 · Cited by 155
Kim, H. A., Ling, B., & Ratner, N. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.862 · Cited by 152
Self-citationSex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1
Diggs‐Andrews, K. A., Brown, J. A., Gianino, S. M., Rubin, J. B., Wozniak, D. F., & Gutmann, D. H. (2013) · Annals of Neurology · doi:10.1002/ana.24093 · Cited by 152
Prada, C. E., Jousma, E., Rizvi, T. A., Wu, J., Dunn, R. S., Mayes, D. A., Cancelas, J. A., Dombi, E., Kim, M., West, B. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1056-7 · Cited by 146
Self-citationBrems, H., Park, C., Maertens, O., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1752 · Cited by 144
Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis
Dai, C., Santagata, S., Tang, Z., Shi, J., Cao, J., Kwon, H., Bronson, R. T., Whitesell, L. J., & Lindquist, S. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62727 · Cited by 140
Katz, D., Lazar, A. J., & Lev, D. C. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001227 · Cited by 139
Nf1 and Gmcsf Interact in Myeloid Leukemogenesis
Birnbaum, R. A., O'Marcaigh, A. S., Wardak, Z., Zhang, Y., Dranoff, G., Jacks, T., Clapp, D. W., & Shannon, K. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80415-3 · Cited by 138
Sung, L., Anderson, J. R., Arndt, C., Raney, R. B., Meyer, W. H., & Pappo, A. S. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.02.026 · Cited by 133
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
Chang, T. Y., Krisman, K., Theobald, E. H., Xu, J., Akutagawa, J., Lauchle, J., Kogan, S. C., Braun, B. S., & Shannon, K. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63193 · Cited by 130
Gutmann, D. H., McLellan, M. D., Hussain, I., Wallis, J. W., Fulton, L., Fulton, R. S., Magrini, V. J., Demeter, R., Wylie, T., Kandoth, C., et al. (2012) · Genome Research · doi:10.1101/gr.142604.112 · Cited by 130
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1
Stevenson, D. A., Birch, P. H., Friedman, J. M., Viskochil, D. H., Balestrazzi, P., Boni, S., Buske, A., Korf, B. R., Niimura, M., Pivnick, E. K., et al. (1999) · American Journal of Medical Genetics · Cited by 130
Mantripragada, K. K., Spurlock, G., Kluwe, L., Chuzhanova, N. A., Ferner, R. E., Frayling, I. M., Dumanski, J. P., Guha, A., Mautner, V., & Upadhyaya, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1305 · Cited by 129
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Meric‐Bernstam, F., Frampton, G. M., Ferrer-Lozano, J., Yelensky, R., Fidalgo, J. A. P., Wang, Y., Palmer, G. A., Ross, J. S., Miller, V. A., Su, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0482 · Cited by 129
Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations
MacInnes, A. W., Amsterdam, A., Whittaker, C. A., Hopkins, N. H., & Lees, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805036105 · Cited by 127
A novel bipartite phospholipid‐binding module in the neurofibromatosis type 1 protein
D’Angelo, I., Welti, S., Bonneau, F., & Scheffzek, K. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400602 · Cited by 125
Schwann Cell Proliferative Responses to cAMP andNf1Are Mediated by Cyclin D1
Kim, H. A., Ratner, N., Roberts, T. M., & Stiles, C. D. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01110.2001 · Cited by 122
Self-citationPatwardhan, P. P., Surriga, O., Beckman, M. J., de Stanchina, E., DeMatteo, R. P., Tap, W. D., & Schwartz, G. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2576 · Cited by 122
Rb and TP53 Pathway Alterations in Sporadic and NF1-Related Malignant Peripheral Nerve Sheath Tumors
Birindelli, S., Perrone, F., Oggionni, M., Lavarino, C. E., Pasini, B., Vergani, B., Ranzani, G. N., Pierotti, M. A., & Pilotti, S. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780293 · Cited by 121
Bottillo, I., Ahlquist, T. C., Brekke, H. R., Danielsen, S. A., van den Berg, E., Mertens, F., Lothe, R. A., & Dallapiccola, B. (2008) · The Journal of Pathology · doi:10.1002/path.2494 · Cited by 118
Reduced microglial CX3CR1 expression delays neurofibromatosis‐1 glioma formation
Pong, W. W., Higer, S. B., Gianino, S. M., Emnett, R. J., & Gutmann, D. H. (2012) · Annals of Neurology · doi:10.1002/ana.23813 · Cited by 116
Cells of Origin in the Embryonic Nerve Roots for NF1-Associated Plexiform Neurofibroma
Chen, Z., Liu, C., Patel, A. J., Liao, C.-P., Wang, Y., & Le, L. Q. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.009 · Cited by 112
Innate Neural Stem Cell Heterogeneity Determines the Patterning of Glioma Formation in Children
Lee, D. Y., Gianino, S. M., & Gutmann, D. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.036 · Cited by 110
Susceptible Stages in Schwann Cells for NF1-Associated Plexiform Neurofibroma Development
Le, L. Q., Liu, C., Shipman, T. E., Chen, Z., Suter, U., & Parada, L. F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4577 · Cited by 110
Cyclic AMP Suppression Is Sufficient to Induce Gliomagenesis in a Mouse Model of Neurofibromatosis-1
Warrington, N. M., Gianino, S. M., Jackson, E. N., Goldhoff, P., Garbow, J. R., Piwnica-Worms, D. R., Gutmann, D. H., & Rubin, J. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3769 · Cited by 109
The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
Gouzi, J. Y., Moressis, A., Walker, J. A., Apostolopoulou, A. A., Palmer, R. H., Bernards, A., & Skoulakis, E. M. C. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002281 · Cited by 106
Shin, J., Padmanabhan, A., de Groh, E. D., Lee, J.-S., Haidar, S., Dahlberg, S. E., Guo, F., He, S., Wolman, M. A., Granato, M., et al. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009779 · Cited by 103
Tumorigenic Properties of Neurofibromin-Deficient Neurofibroma Schwann Cells
Muir, D., Neubauer, D., Lim, I. T., Yachnis, A. T., & Wallace, M. R. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63992-2 · Cited by 102
Watson, A. L., Rahrmann, E. P., Moriarity, B. S., Choi, K., Conboy, C. B., Greeley, A. D., Halfond, A. L., Anderson, L. K., Wahl, B. R., Keng, V. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0081 · Cited by 102
Self-citationTan, X., Wang, S., Yang, B., Zhu, L., Yin, B., Chao, T., Zhao, J., Yuan, J., Qiang, B., & Peng, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049570 · Cited by 100
Tan, M., Zhao, Y., Kim, S.-J., Liu, M., Jia, L., Saunders, T. L., Zhu, Y., & Sun, Y. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.09.014 · Cited by 94
Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation
Anastasaki, C., & Gutmann, D. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu389 · Cited by 91
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor
Perrone, F., Riva, L. D., Orsenigo, M., Losa, M., Jocollé, G., Millefanti, C., Pastore, E., Gronchi, A., Pierotti, M. A., & Pilotti, S. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-003 · Cited by 91
Sec14p-like domains in NF1 and Dbl-like proteins indicate lipid regulation of Ras and Rho signaling
Aravind, L., Neuwald, A. F., & Ponting, C. P. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80127-4 · Cited by 89
Feldmann, R., Denecke, J., Grenzebach, M., Schuierer, G. R., & Weglage, J. (2003) · Neurology · doi:10.1212/01.wnl.0000098881.95854.5f · Cited by 89
NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Dodd, R. D., Mito, J. K., Eward, W. C., Chitalia, R., Sachdeva, M., Ma, Y., Barretina, J., Dodd, L. G., & Kirsch, D. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0189 · Cited by 89
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy
Holtkamp, N., Malzer, E., Zietsch, J., Okuducu, A. F., Mucha, J., Mawrin, C., Mautner, V., Schildhaus, H., & von Deimling, A. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-053 · Cited by 88
Patel, A. J., Liao, C.-P., Chen, Z., Liu, C., Wang, Y., & Le, L. Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.001 · Cited by 87
Ribeiro, S., Napoli, I., White, I. J., Parrinello, S., Flanagan, A. M., Suter, U., Parada, L. F., & Lloyd, A. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.033 · Cited by 86
Optimizing biologically targeted clinical trials for neurofibromatosis
Gutmann, D. H., Blakeley, J. O., Korf, B. R., & Packer, R. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.772979 · Cited by 85
Tanaka, K., Nakafuku, M., Tamanoi, F., Kaziro, Y., Matsumoto, K., & Toh‐e, A. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4303-4313.1990 · Cited by 85
A Novel Cytokine Pathway Suppresses Glial Cell Melanogenesis after Injury to Adult Nerve
Rizvi, T. A., Huang, Y., Sidani, A., Atit, R. P., Largaespada, D. A., Boissy, R. E., & Ratner, N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09831.2002 · Cited by 80
Self-citationValosin-containing protein and neurofibromin interact to regulate dendritic spine density
Wang, H.-F., Shih, Y.-T., Chen, C.-Y., Chao, H.-W., Lee, M.-J., & Hsueh, Y.-P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45677 · Cited by 80
Welti, S., Fraterman, S., D’Angelo, I., Wilm, M. S., & Scheffzek, K. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.055 · Cited by 78
Wolman, M. A., de Groh, E. D., McBride, S. M. J., Jongens, T. A., Granato, M., & Epstein, J. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.054 · Cited by 78
Mawrin, C., Kirches, E., Boltze, C., Dietzmann, K., Roessner, A., & Schneider‐Stock, R. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-001-0550-4 · Cited by 73
Patel, A. V., Eaves, D. W., Jessen, W. J., Rizvi, T. A., Ecsedy, J., Qian, M. G., Aronow, B. J., Perentesis, J. P., Serra, E., Cripe, T. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1072 · Cited by 72
Self-citationVariable expression of neurofibromatosis 1 in monozygotic twins
Rieley, M. B., Stevenson, D. A., Viskochil, D. H., Tinkle, B. T., Martin, L. J., & Schorry, E. K. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33851 · Cited by 69
Mayes, D. A., Rizvi, T. A., Titus, H. E., Oberst, R., Ciraolo, G. M., Vorhees, C. V., Robinson, A. P., Miller, S. D., Cancelas, J. A., Stemmer-Rachamimov, A. O., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.011 · Cited by 69
Self-citationMayes, D. A., Rizvi, T. A., Cancelas, J. A., Kolasinski, N. T., Ciraolo, G. M., Stemmer-Rachamimov, A. O., & Ratner, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4558 · Cited by 68
Self-citationIdentifying the Ubiquitin Ligase Complex That Regulates the NF1 Tumor Suppressor and Ras
Hollstein, P. E., & Cichowski, K. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0146 · Cited by 67
Gutmann, D. H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3009 · Cited by 65
Al‐Kindy, A., Chuzhanova, N. A., Kini, U., Cooper, D. N., & Upadhyaya, M. (2012) · Human Genomics · doi:10.1186/1479-7364-6-12 · Cited by 64
Tokuo, H., Yunoue, S., Feng, L., Kimoto, M., Tsuji, H., Ono, T., Saya, H., & Araki, N. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02309-2 · Cited by 60
MicroRNA-193b Enhances Tumor Progression via Down Regulation of Neurofibromin 1
Lenarduzzi, M., Hui, A. B., Alajez, N. M., Shi, W., Williams, J. P., Yue, S., O’Sullivan, B., & Liu, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053765 · Cited by 60
Park, S., Sawitzki, B., Kluwe, L., Mautner, V. F., Holtkamp, N., & Kurtz, A. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-109 · Cited by 58
Ko, J. M., Sohn, Y. B., Jeong, S. Y., Kim, H.-J., & Messiaen, L. M. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.02.004 · Cited by 58
Neurofibromin Is the Major Ras Inactivator in Dendritic Spines
Oliveira, A. F., & Yasuda, R. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3096-13.2014 · Cited by 58
The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
Luscan, A., Shackleford, G., Masliah‐Planchon, J., Laurendeau, I., Ortonne, N., Varin, J., Lallemand, F., Leroy, K., Dumaine, V., Hivelin, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0780 · Cited by 57
Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors
Spyra, M., Kluwe, L., Hagel, C., Nguyen, R., Panse, J., Kurtz, A., Mautner, V. F., Rabkin, S. D., & Demestre, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021099 · Cited by 55
Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors
Bodempudi, V., Yamoutpoor, F., Pan, W., Dudek, A. Z., Esfandyari, T., Piedra, M., Babovic‐Vuksanovic, D., Woo, R. A., Mautner, V. F., Kluwe, L., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01153-08 · Cited by 53
Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia
Boudry‐Labis, E., Roche‐Lestienne, C., Nibourel, O., Boissel, N., Terré, C., Pérot, C., Éclache, V., Gachard, N., Tigaud, I., Plessis, G., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23403 · Cited by 51
Williams, J. P., Wu, J., Johansson, G., Rizvi, T. A., Miller, S. C., Geiger, H., Malik, P., Li, W., Mukouyama, Y., Cancelas, J. A., et al. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.10.003 · Cited by 48
Self-citationMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1
Brundage, M. E., Tandon, P., Eaves, D. W., Williams, J. P., Miller, S. J., Hennigan, R. F., Jegga, A. G., Cripe, T. P., & Ratner, N. (2014) · Oncogene · doi:10.1038/onc.2013.506 · Cited by 48
Self-citationNf1 RasGAP Inhibition of LIMK2 Mediates a New Cross-Talk between Ras and Rho Pathways
Vallée, B., Doudeau, M., Godin, F., Gombault, A., Tchalikian-Cosson, A., de Tauzia, M.-L., & Bénédetti, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047283 · Cited by 44
Hummel, T. R., Jessen, W. J., Miller, S. J., Kluwe, L., Mautner, V. F., Wallace, M. R., Lázaro, C., Page, G. P., Worley, P. F., Aronow, B. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0613 · Cited by 42
Self-citationClinical and molecular analysis of RASopathies in a group of Turkish patients
Şimşek‐Kiper, P. Ö., Alanay, Y., Gülhan, B., Lißewski, C., Türkyılmaz, M. D., Alehan, D., Çetin, M., Ütine, G. E., Zenker, M., & Boduroğlu, K. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01875.x · Cited by 41
Neurofibromatosis Type 1 Alternative Splicing Is a Key Regulator of Ras Signaling in Neurons
Hinman, M. N., Sharma, A., Luo, G., & Lou, H. J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00019-14 · Cited by 40
Widemann, B. C., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Dombi, E., Baldwin, A. M., Whitcomb, P. O., Martin, S. C., Gillespie, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10018 · Cited by 39
Rodenhiser, D. I., Andrews, J. D., Mancini, D. N., Jung, J.-K., & Singh, S. M. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(96)00171-6 · Cited by 38
Neurofibromin 1 Is a miRNA Target in Neurons
Paschou, M., & Doxakis, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046773 · Cited by 36
Zhang, G., Hoersch, S., Amsterdam, A., Whittaker, C. A., Beert, E., Catchen, J., Farrington, S. M., Postlethwait, J. H., Legius, E., Hopkins, N. H., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003734 · Cited by 36
DDAH1 Deficiency Attenuates Endothelial Cell Cycle Progression and Angiogenesis
Zhang, P., Xu, X., Hu, X., Wang, H., Fassett, J. T., Huo, Y., Chen, Y., & Bache, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079444 · Cited by 34
Chau, V., Lim, S. K., Mo, W., Liu, C., Patel, A. J., McKay, R. M., Wei, S., Posner, B. A., Brabander, J. K. D., Williams, N. S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1934 · Cited by 32
Buchstaller, J., McKeever, P. E., & Morrison, S. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.027 · Cited by 31
The Plexiform Neurofibroma Microenvironment
Yang, F., Staser, K. W., & Clapp, D. W. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0115-x · Cited by 30
Yoshimi, A., Kojima, S., & Hirano, N. (2009) · Pediatric Drugs · doi:10.2165/11316200-000000000-00000 · Cited by 26
In Vivo Regulation of TGF-β by R-Ras2 Revealed through Loss of the RasGAP Protein NF1
Patmore, D. M., Welch, S., Fulkerson, P. C., Wu, J., Choi, K., Eaves, D. W., Kordich, J. J., Collins, M. H., Cripe, T. P., & Ratner, N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1972 · Cited by 26
Self-citationArlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12
Schaick, J. C. A.-V., Kim, S., DiFabio, C., Lee, M., Broman, K. W., & Reilly, K. M. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor206 · Cited by 26
Overactivation of Ras signaling pathway in CD133+ MPNST cells
Borrego-Diaz, E., Terai, K., Lialyte, K., Wise, A. L., Esfandyari, T., Behbod, F., Mautner, V. F., Spyra, M., Taylor, S. A., Parada, L. F., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0852-1 · Cited by 21
Peacock, J. D., Cherba, D., Kampfschulte, K., Smith, M., Monks, N. R., Webb, C. P., & Steensma, M. R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-213 · Cited by 20
Farrer, R. G., Farrer, J., & DeVries, G. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442244 · Cited by 11
Wood, M. D., Rawe, M., Johansson, G., Pang, S., Soderquist, R. S., Patel, A. V., Nelson, S. L., Seibel, W. L., Ratner, N., & Sánchez, Y. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0309 · Cited by 11
Self-citationColombo, S., Paiardi, C., Pardons, K., Winderickx, J., & Martegani, E. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.001 · Cited by 9
Functional MHC Class II Is Upregulated in Neurofibromin-Deficient Schwann Cells
Reuß, D., Mucha, J., Holtkamp, N., Müller, U., Berlien, H., Mautner, V., Ehemann, V., Platten, M., Scheffzek, K., & von Deimling, A. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.488 · Cited by 6
Cited by
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
Self-citationExome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J. P., Ma, S., Cheng, E., Straub, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3361 · Cited by 402
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Metadata
- Authors
- Ratner, N., & Miller, S. J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-04-16
- Volume
- 15
- Issue
- 5
- Pages
- 290-301
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2010105281
- Cited by
- 493
- References
- 192
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.